Thromboxane synthase expression and thromboxane A2 production in the atherosclerotic lesion

Journal of Molecular Medicine

Volumn 88, Issue 8, 2010, Pages 795-806

  Gabrielsen, Anders ^a,b   Qiu, Hong ^a   Bäck, Magnus ^a   Hamberg, Mats ^a   Hemdahl, Anne Louise ^a   Agardh, Hanna ^a   Folkersen, Lasse ^a   Swedenborg, Jesper ^b   Hedin, Ulf ^b   Paulsson Berne, Gabrielle ^a   Haeggström, Jesper Z ^a   Hansson, Göran K ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atherosclerosis; Gene expression; Inflammation; Prostaglandins; Thromboxane

Indexed keywords

ARACHIDONIC ACID; CD163 ANTIGEN; CD3 ANTIGEN; CD68 ANTIGEN; FIBRINOGEN RECEPTOR; FUREGRELATE; LIPOPOLYSACCHARIDE; MESSENGER RNA; THROMBOXANE A2; THROMBOXANE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY WALL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOSIS; ANIMAL; C57BL MOUSE; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; ATHEROSCLEROSIS; FEMALE; GENE EXPRESSION; HUMANS; MICE; MICE, INBRED C57BL; RNA, MESSENGER; THROMBOXANE A2; THROMBOXANE-A SYNTHASE;

EID: 77956460552     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00109-010-0621-6     Document Type: Article

References (37)

1. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-1695
2. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C et al (2003) From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part II. Circulation 108:1772-1778 (Pubitemid 37296082)
3. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P et al (2003) From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation 108:1664-1672 (Pubitemid 37243650)
4. Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72:2994-2998
5. Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ 2nd (1988) Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med 319:761-767
6. Oates JA, FitzGerald GA, Branch RA, Jackson EK, Knapp HR, Roberts LJ 2nd (1988) Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med 319:689-698
7. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:234S-264S
8. Shen RF, Tai HH (1998) Thromboxanes: synthase and receptors. J Biomed Sci 5:153-172
9. Yu IS, Lin SR, Huang CC, Tseng HY, Huang PH, Shi GY, Wu HL, Tang CL, Chu PH, Wang LH, Wu KK, Lin SW (2004) TXAS-deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate-induced death. Blood 104:135-142
10. Samuelsson B, Hamberg M, Malmsten C, Svensson J (1976) The role of prostaglandin endoperoxides and thromboxanes in platelet aggregation. Adv Prostaglandin Thromboxane Res 2:737-746
11. Takayama K, Yuhki K, Ono K, Fujino T, Hara A, Yamada T, Kuriyama S, Karibe H, Okada Y, Takahata O et al (2005) Thromboxane A2 and prostaglandin F2alpha mediate inflammatory tachycardia. Nat Med 11:562-566
12. Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B (1976) Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature 261:558-560
13. Fitzgerald GA (2004) Coxibs and cardiovascular disease. N Engl J Med 351:1709-1711
14. Mehta J, Roberts A (1983) Human vascular tissues produce thromboxane as well as prostacyclin. Am J Physiol 244: R839-R844
15. Pawlowski NA, Kaplan G, Hamill AL, Cohn ZA, Scott WA (1983) Arachidonic acid metabolism by human monocytes. Studies with platelet-depleted cultures. J Exp Med 158:393-412
16. Kennedy MS, Stobo JD, Goldyne ME (1980) In vitro synthesis of prostaglandins and related lipids by populations of human peripheral blood mononuclear cells. Prostaglandins 20:135-145
17. Neri Serneri GG, Gensini GF, Poggesi L, Modesti PA, Rostagno C, Boddi M, Gori AM, Martini F, Ieri A, Margheri M, Abbate R (1994) The role of extraplatelet thromboxane A2 in unstable angina investigated with a dual thromboxane A2 inhibitor: importance of activated monocytes. Coron Artery Dis 5:137-145
18. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, Arai H, Oida H, Yurugi-Kobayashi T, Yamashita JK et al (2004) Roles of thromboxane A (2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 114:784-794
19. Cayatte AJ, Du Y, Oliver-Krasinski J, Lavielle G, Verbeuren TJ, Cohen RA (2000) The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apoE-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol 20:1724-1728
20. Cyrus T, Yao Y, Ding T, Dogne JM, Pratico D (2007) Thromboxane receptor blockade improves the antiatherogenic effect of thromboxane A2 suppression in LDLR KO mice. Blood 109:3291-3296
21. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373-2383
22. Caligiuri G, Levy B, Pernow J, Thoren P, Hansson GK (1999) Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. Proc Natl Acad Sci USA 96:6920-6924
23. Martinez FO, Sica A, Mantovani A, Locati M (2008) Macrophage activation and polarization. Front Biosci 13:453-461
24. Back M, Qiu H, Haeggstrom JZ, Sakata K (2004) Leukotriene B4 is an indirectly acting vasoconstrictor in guinea pig aorta via an inducible type of BLT receptor. Am J Physiol Heart Circ Physiol 287: H419-H424
25. Redgrave JN, Lovett JK, Gallagher PJ, Rothwell PM (2006) Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms: the Oxford Plaque Study. Circulation 113:2320-2328
26. Kleindorfer D, Panagos P, Pancioli A, Khoury J, Kissela B, Woo D, Schneider A, Alwell K, Jauch E, Miller R, Moomaw C, Shukla R, Broderick JP (2005) Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 36:720-723
27. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ (2002) Expression of Toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105:1158-1161
28. Hwang D (2001) Modulation of the expression of cyclooxygenase-2 by fatty acids mediated through Toll-like receptor 4-derived signaling pathways. Faseb J 15:2556-2564 (Pubitemid 33131082)
29. Back M, Bu DX, Branstrom R, Sheikine Y, Yan ZQ, Hansson GK (2005) Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA 102:17501-17506
30. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, Staels B, Chinetti-Gbaguidi G (2007) PPARgamma activation primes human monocytes into alternative M2 macrophages with antiinflammatory properties. Cell Metab 6:137-143
31. Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ (1999) Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59:4574-4577
32. Ashton AW, Ware JA (2004) Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. Circ Res 95:372-379
33. Ashton AW, Cheng Y, Helisch A, Ware JA (2004) Thromboxane A2 receptor agonists antagonize the proangiogenic effects of fibroblast growth factor-2: role of receptor internalization, thrombospondin-1, and alpha (v) beta3. Circ Res 94:735-742
34. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, Lo KM, Gillies S, Javaherian K, Folkman J (2003) Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 100:4736-4741
35. Kabashima K, Murata T, Tanaka H, Matsuoka T, Sakata D, Yoshida N, Katagiri K, Kinashi T, Tanaka T, Miyasaka M, Nagai H, Ushikubi F, Narumiya S (2003) Thromboxane A2 modulates interaction of dendritic cells and T cells and regulates acquired immunity. Nat Immunol 4:694-701
36. Ishizuka T, Matsumura K, Matsui T, Takase B, Kurita A (2003) Ramatroban, a thromboxane A2 receptor antagonist, prevents macrophage accumulation and neointimal formation after balloon arterial injury in cholesterol-fed rabbits. J Cardiovasc Pharmacol 41:571-578
37. Egan KM, Wang M, Fries S, Lucitt MB, Zukas AM, Pure E, Lawson JA, FitzGerald GA (2005) Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111:334-342